Skip to main content
Clinical Trials/ISRCTN22114173
ISRCTN22114173
Completed
未知

Highly Active Antiretroviral Treatment (HAART) of Human Immunodeficiency Virus (HIV)-infection in a town in Cameroon: randomised controlled study to suggest which treatment starting point is most beneficial for the patients

Institute of Community Medicine, University of Tromsø (Norway)0 sites100 target enrollmentJuly 6, 2007

Overview

Phase
未知
Intervention
Not specified
Conditions
HIV infection
Sponsor
Institute of Community Medicine, University of Tromsø (Norway)
Enrollment
100
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 6, 2007
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Institute of Community Medicine, University of Tromsø (Norway)

Eligibility Criteria

Inclusion Criteria

  • 1\. Treatment naive Human Immunodeficiency Virus (HIV)\-infected individuals
  • 2\. 16 years of age or older
  • 3\. CD4 count between 450 and 250 cells/mm^3

Exclusion Criteria

  • 1\. If patient fulfils current indications for immediate treatment: CD4 less than 250 cells/mm^3 or WHO clinical stage 3 or 4
  • 2\. If CD4 is currently greater than 450 cells/mm^3 . This is because patient will probably not start Anti\-Retroviral Therapy (ART) during the first year to come

Outcomes

Primary Outcomes

Not specified

Similar Trials